G
GSK
Global biopharma company developing medicines and vaccines to prevent and treat disease
About GSK
GSK (GlaxoSmithKline) is a global healthcare company focused on improving the quality of human life by developing innovative medicines, vaccines, and consumer healthcare products. The company operates in three primary areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. GSK serves a wide range of clients, including patients, healthcare professionals, and governments worldwide.
In the Pharmaceuticals segment, GSK researches and develops medicines to treat various diseases, including respiratory conditions, HIV, oncology, and immuno-inflammation. The Vaccines segment focuses on creating vaccines to prevent illnesses such as influenza, shingles, and COVID-19. The Consumer Healthcare division offers over-the-counter products for wellness, oral health, nutrition, and skin health.
GSK operates in the highly competitive and regulated global healthcare market. The company’s business model revolves around extensive research and development (R&D) to bring new products to market. GSK invests heavily in scientific innovation to stay ahead of emerging health threats and meet the evolving needs of patients.
GSK generates revenue primarily through the sale of its pharmaceutical products, vaccines, and consumer healthcare items. The company also collaborates with other biotech firms and governments, which can include agreements for the purchase of treatments, such as their COVID-19 therapy, sotrovimab. Additionally, GSK offers support programs to help patients afford their medications, ensuring broader access to their products.
In summary, GSK is a science-led healthcare company dedicated to developing and delivering a wide range of innovative products that improve health outcomes globally. The company’s commitment to R&D, strategic partnerships, and patient support programs are key drivers of its growth and performance.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1891
- Headquarters
- London, United Kingdom
- Listing
- IPO 1984
- Employees
- 95,528
- Open positions
- 735
- Dealroom signal
- 64.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Recycling, Biotechnology, Vaccines, Infections and Infectious Diseases, Immune System, Waste Reduction, EIT KIC Partners, Horizon Europe
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 62 companies, latest Aug 2026
- Capital deployed
- $1.8B
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBT✓Debt | Aug 2026 | $3.9B | — | Undisclosed | ↗ |
| IPO✓Exit | Jan 1984 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for GSK is 1.7M monthly website visits, up 0% over the last three months. GSK's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
LifeMine TherapeuticsCambridge, United StatesPioneering in genomically-enabled drug discovery approach integrating advanced life science and computational technologies
$752Mvaluation
NuvalentCambridge, United StatesTargeted small-molecule cancer therapies for kinase-driven cancers
$11Bvaluation
35PharmaMontreal, CanadaAdvancing therapeutic biologics to treat cardiopulmonary and metabolic diseases
$950Mvaluation
RAPT TherapeuticsSan Francisco, United StatesDevelops clinical-stage therapies targeting inflammatory and immunological diseases through small-molecule and biologic drug research
$2.2Bvaluation
Boston PharmaceuticalsCambridge, United StatesAcquiring and transforming innovative molecules into differentiated medicines that improve patients’ lives
$1.2Bvaluation
Ouro MedicinesSouth San Francisco, United StatesBiotechnology firm advancing immune reset therapeutics for chronic immune-mediated diseases with a robust clinical pipeline
$1.7Bvaluation
IDRxPlymouth, United StatesIntelligently designed precision combinations to transform cancer care
$1Bvaluation
Relation TherapeuticsLondon, United KingdomUsing machine learning to improve drug discovery
$220Mvaluation
Chimagen BiosciencesPudong, ChinaDeveloping innovative medicine to address the unmet medical needs in the area of oncology
$400Mvaluation
AsceneuronLausanne, SwitzerlandDevelops effective therapeutics for orphan tauopathies
$400Mvaluation
Elsie BiotechnologiesSan Diego, United StatesElsie Biotechnologies is unlocking the full potential of RNA therapeutics to treat undruggable diseases
$50Mvaluation
ElegenSan Carlos, United StatesElegen is a biotechnology company that develops microfluidic technology
$140Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors2 additional known investors
InterWest Partners
US Biomedical Advanced Research and Development Authority
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about GSK on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GSK’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.